¡Òäé¹ËÒÇѳâä´×éÍÂÒâ´Â¡ÒÃà¾ÒÐàª×éÍÇѳâä

â´Â¡ÒÃÂéÍÁàª×éÍÇѳâä AFB ¡è͹¶éÒ AFB+ ¨Ö§·Ó¡ÒÃà¾ÒÐàª×éÍÇѳâäµèÍä»

à¾ÒÐàª×éÍ¢Öé¹ äǵèÍÂÒäÍâ«ä¹ÍЫԴáÅÐÃÔá¿Á»Ô«Ô¹ á¹Ð¹ÓãËé·èÒ¹

  1. ËÂØ´ÂÒÍÕá¸ÁºÔÇ·ÍÅ
  2. ãËéÂÒäÍâ«ä¹ÍЫԴ ÃÔá¿Á»Ô«Ô¹ áÅÐä¾ÃÒ«Ô¹ÒäÁ´ìµèÍ仨¹¤Ãº 2 à´×͹áÅéÇà»ÅÕè¹à»ç¹äÍâ«ä¹ÍЫԴáÅÐÃÔá¿Á»Ô«Ô¹ÍÕ¡ 4 à´×͹
à¾ÒÐàª×éÍ¢Öé¹ äǵèÍÃÔá¿Á»Ô«Ô¹áµè´×é͵èÍäÍâ«ä¹ÍЫԴ á¹Ð¹ÓãËé·èÒ¹
  1. ËÂØ´ÂÒäÍâ«ä¹ÍЫԴ
  2. ãËéÂÒ ÃÔá¿Á»Ô«Ô¹, ÍÕá¸ÁºÔǵÍÅ áÅÐä¾ÃÒ«Ô¹ÒäÁ´ìµèÍä» ÃÐËÇèÒ§·ÕèÃͼŠ¡ÒÃ·Ó species identification (à¾ÃÒÐÍÒ¨à»ç¹àª×éÍ M.tuberculosis  ËÃ×Í non tuberculosis mycobacteria) áÅÐËÒ¤ÇÒÁäǵèÍÂÒ first áÅÐ second line drugs â´ÂÇÔ¸Õ indirect susceptability «Öè§µéͧãªéàÇÅÒÍÕ¡ 6-8 ÊÑ»´ÒËì (¶éÒ¾ºÇèÒ´×é͵èÍÂÒäÍâ«ä¹ÍЫԴà¾Õ§µÑÇà´ÕÂÇ ãËéÂÒÃÔá¿Á»Ô«Ô¹ ÍÕá¸ÁºÔÇ·ÍÅáÅÐä¾ÃÒ«Ô¹ÒäÁ´ìµèÍ仨¹¤Ãº 6 à´×͹à»ç¹ÍÂèÒ§¹éÍ ÍÒ¨ãËé¹Ò¹¶Ö§ 9 à´×͹)
à¾ÒÐàª×éÍ¢Öé¹ äǵèÍÂÒäÍâ«ä¹ÍЫԴáµè´×é͵èÍÃÔá¿Á»Ô«Ô¹ á¹Ð¹ÓãËé·èÒ¹
  1. ËÂØ´ÂÒÃÔá¿Á»Ô«Ô¹
  2. ãËéÂÒäÍâ«ä¹ÍЫԴ, ÍÕá¸ÁºÔǵÍÅ áÅÐä¾ÃÒ«Ô¹ÒäÁ´ìµèÍä»
  3. à¾ÔèÁÂÒ ofloxacin áÅÐ streptomycin ÃÐËÇèÒ§·ÕèÃͼŠ¡ÒÃ·Ó species identification (à¾ÃÒÐÍÒ¨à»ç¹àª×éÍ M.tuberculosis  ËÃ×Í non tuberculosis mycobacteria) áÅÐËÒ¤ÇÒÁäǵèÍÂÒ first áÅÐ second line drugs â´ÂÇÔ¸Õ indirect susceptability «Öè§µéͧãªéàÇÅÒÍÕ¡ 6-8 ÊÑ»´ÒËì
à¾ÒÐàª×éÍ¢Öé¹ ´×é͵èÍ·Ñé§ÂÒäÍâ«ä¹ÍЫԴáÅд×é͵èÍÃÔá¿Á»Ô«Ô¹ ¤×Íà»ç¹ MDR áµèÍÒ¨à»ç¹ non tuberculosis mycobacteria á¹Ð¹ÓãËé·èÒ¹
  1. ËÂØ´ÂÒÂÒäÍâ«ä¹ÍЫԴáÅÐÃÔá¿Á»Ô«Ô¹
  2. ãËéÂÒÍÕá¸ÁºÔǵÍÅ, ä¾ÃÒ«Ô¹ÒäÁ´ìµèÍä»
  3. à¾ÔèÁÂÒ PAS*, ofloxacin áÅÐ kanamycin ÃÐËÇèÒ§¹ÕéÃͼŠspecies identification áÅÐËÒ¤ÇÒÁäǵèÍÂÒ first áÅÐ second line drugs â´ÂÇÔ¸Õ indirect susceptability «Öè§µéͧãªéàÇÅÒÍÕ¡ 6-8 ÊÑ»´ÒËì (¶éÒʧÊÑ non tuberculosis mycobacteria â´Â੾ÒÐã¹ AIDS ÍÒ¨ãËéÂÒ azithromycin ËÃ×Í clarithromycin ÃèÇÁ´éÇ ¶éҼŠspecies identification ¾ºÇèÒà»ç¹ MDR TB ãËéËÂØ´ÂÒµÑǹÕéä´é)
    * ÍÒ¨à»ÅÕè¹à»ç¹ ethionamide ËÃ×Í cycloserine


âäÇѳâä